Background:
We aimed to investigate treatment response, survival profiles, safety profiles, and predictive factors of drug-eluting beads-transarterial chemoembolization (DEB-TACE) with CalliSpheres Microspheres (CSM) in treating Chinese hepatocellular carcinoma (HCC) patients.
Methods:
A total of 66 HCC patients about to receive DEB-TACE with CSM therapy were consecutively enrolled in this prospective cohort study. Treatment response was recorded. Besides, progression-free survival (PFS) and overall survival (OS) were also recorded. All adverse events including pain, nausea, vomiting, fever, and liver function damage were recorded during hospitalization.
Results:
37.9% of patients achieved complete response (CR) and 81.8% of patients achieved an objective response rate (ORR). For survival, mean PFS and OS were 13.7 (11.7-15.8) months and 18.8 (95% CI: 16.3-21.2) months, respectively. Multivariate logistic regression analysis revealed that a number of nodules ≥2 was an independent factor for worse CR; moreover, multivariate Cox's regression analysis disclosed that largest sample size ≥5 cm was an independent factor for shorter PFS, and Child-Pugh B and BCLC stage B/C were independent predictive factors for unfavorable OS. As to AEs, numbers of patients suffered liver function damage, pain, nausea, vomiting, and fever were 29 (43.9%), 27 (40.9%), 22 (33.3%), 13 (19.7%), and 37 (56.1%), respectively.
Conclusion:
Drug-eluting beads-transarterial chemoembolization with CSM is an effective and tolerated treatment for Chinese HCC patients, and number of nodules ≥2, largest nodule size ≥5 cm, Child-Pugh stage B, and BCLC stage B/C correlates with unfavorable prognosis.
Citing Articles
5-Fluorouracil combined with CalliSphere drug-eluting beads or conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score weighting analysis.
Wei M, Zhang P, Yang C, Luo M, Zeng C, Zhang Y
Sci Rep. 2024; 14(1):25588.
PMID: 39462077
PMC: 11513126.
DOI: 10.1038/s41598-024-77531-2.
Neutrophil-to-lymphocyte ratio as an index of treatment response to trans-arterial chemoembolization in hepatocellular carcinoma.
Shayegan N, Ayoobi N, Mohammadi E, Saberi H, Salahshour F, Alborzi F
Gastroenterol Hepatol Bed Bench. 2024; 17(3):253-259.
PMID: 39308535
PMC: 11413382.
DOI: 10.22037/ghfbb.v17i3.2925.
Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
Peng N, Mao L, Tao Y, Xiao K, Yuan G, He S
World J Surg Oncol. 2022; 20(1):254.
PMID: 35941634
PMC: 9361543.
DOI: 10.1186/s12957-022-02717-9.
Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma.
Huang J, Huang W, Zhan M, Guo Y, Liang L, Cai M
J Hepatocell Carcinoma. 2021; 8:1445-1458.
PMID: 34858889
PMC: 8631985.
DOI: 10.2147/JHC.S339379.
Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma.
Razi M, Jianping G, Xu H, Ahmed M
J Interv Med. 2021; 4(1):11-14.
PMID: 34805941
PMC: 8562211.
DOI: 10.1016/j.jimed.2020.10.006.
Advances in the treatment of hepatocellular carcinoma using drug-eluting beads.
Wei G, Yang J
J Interv Med. 2021; 3(3):122-127.
PMID: 34805921
PMC: 8562162.
DOI: 10.1016/j.jimed.2020.07.003.
Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients.
Zhao G, Liu S, Chen S, Ren Z, Li C, Bian J
Drug Deliv. 2021; 28(1):1356-1362.
PMID: 34180755
PMC: 8245102.
DOI: 10.1080/10717544.2021.1943057.
Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis.
Liang B, Makamure J, Shu S, Zhang L, Sun T, Zheng C
Front Oncol. 2021; 11:576232.
PMID: 33796448
PMC: 8008112.
DOI: 10.3389/fonc.2021.576232.
Evaluating the predictive power of circulating tumor cells for the prognosis of transarterial chemoembolization treatment on patients with advanced hepatocellular carcinoma.
Deng J, Chen W, Wu X, Zhou Y, Li J
Medicine (Baltimore). 2021; 100(1):e24060.
PMID: 33429769
PMC: 7793346.
DOI: 10.1097/MD.0000000000024060.
Targeting Ca Signaling in the Initiation, Promotion and Progression of Hepatocellular Carcinoma.
Ali E, Rychkov G, Barritt G
Cancers (Basel). 2020; 12(10).
PMID: 32987945
PMC: 7600741.
DOI: 10.3390/cancers12102755.
Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma.
Zhang Y, Zhang M, Fan X, Mao D, Ding Q, Zhuang L
World J Gastrointest Surg. 2020; 12(8):355-368.
PMID: 32903981
PMC: 7448208.
DOI: 10.4240/wjgs.v12.i8.355.
Clinical effect of bronchial arterial infusion chemotherapy and CalliSpheres drug-eluting beads in patients with stage II-IV lung cancer: A prospective cohort study.
Shang B, Li J, Wang X, Li D, Liang B, Wang Y
Thorac Cancer. 2020; 11(8):2155-2162.
PMID: 32603550
PMC: 7396372.
DOI: 10.1111/1759-7714.13522.
An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres Microspheres in treating Chinese hepatocellular carcinoma patients.
Zhang X, Lin X, Qiu H, Peng Z
J Clin Lab Anal. 2019; 33(8):e22975.
PMID: 31328832
PMC: 6805711.
DOI: 10.1002/jcla.22975.
